期刊文献+

地高辛联合卡维地洛治疗缺血性心肌病心力衰竭并心房颤动的疗效观察 被引量:4

暂未订购
导出
摘要 目的探讨地高辛联合卡维地洛治疗缺血性心肌病心力衰竭合并心房颤动的临床效果。方法将62例缺血性心肌病心力衰竭合并心房颤动患者随机分为观察组32例和对照组30例。对照组予地高辛0.25mg/d,观察组采用对照组治疗方法治疗1周后加用卡维地洛治疗,2组疗程均为3个月。治疗后观察2组临床疗效及治疗前后6min步行距离、心率、超声心动图指标的变化。结果治疗3个月后,治疗组总有效率为90.6%明显高于对照组的66.7%,差异有统计学意义(P<0.05)。观察组治疗后6min步行距离大于治疗前,且大于对照组,差异均有统计学意义(P<0.05)。2组治疗后静息心率及Holter 24h平均心率、最快心率、最慢心率均明显下降,且观察组下降程度较对照组明显,差异均有统计学意义(P<0.05或P<0.01)。2组治疗后左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)水平降低,每搏量(SV)、每分钟心排血量(CO)及射血分数(EF)水平升高,且观察组改善程度优于对照组,差异均有统计学意义(P<0.05或P<0.01)。结论地高辛联合卡维地洛治疗缺血性心肌病心力衰竭合并心房颤动疗效显著,值得推广应用。
作者 刘月
出处 《临床合理用药杂志》 2013年第4期109-111,共3页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献6

二级参考文献13

共引文献2414

同被引文献42

  • 1张放.充血型缺血性心肌病的诊断与治疗[J].中国循环杂志,1989,4(1):19-21. 被引量:19
  • 2中华人民共和国卫生部.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002.243.
  • 3Krzysztof G, Krzysztof M, Jaroslaw D, et al. Mechanisms of functional mitral regurgitation in ischemic cardiomyopathy determined by transesophageal echocardiography (from the surgical treatment for ischemic heart failure trial)[J]. Am J Cardiol,2013,112(11) :1812-1818.
  • 4Takeshi N, Yasuchika T, Toshiki S, et al. Usefulness of albuminuria as a prognostic indicator in patients with chronic heart failure secondary to isehemic or idiopathic dilated cardiomyopat hy[J]. Am J Cardiol, 2013,111 (8) : 1180-1186.
  • 5Vasiliki B,John TP,Ioannis P,et al. Prognostic value of tissue doppler right ventricular systolic and diastolic function indexes combined with plasma B-type natriuretic peptide in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy[J]. Am J Cardiol, 2010, 105 (2) : 249- 254.
  • 6Ngaage D L, Daly R C, Rosales G, et al. Mitralregurgitation surgery in heart failure due to ischemiccardiomyopathy :a 24-year experience[ J]. J Heart ValveDis,2008,17(3) :251-259.
  • 7Taraz6n E, Rosell6-LletI E, Ortega A, et al. Differentialgene expression of C-type natriuretic peptide and itsrelated molecules in dilated and ischemiccardiomyopathy. A new option for the management ofheart failure[ J]. Int J Cardiol,2014,174(3) :84-86.
  • 8Zabczyk M,Butenas S,Palka I, et al. Active tissue factorand activated factor XI in circulating blood of patientswith systolic heart failure due to ischemiccardiomyopathy [ J ]. Pol Arch Med Wewn, 2010,120(9):334-340.
  • 9Chrusciel P, Rysz J, Banach M. Defining the role oftrimetazidine in the treatment of cardiovasculardisorders : some insights on its role in heart failure andperipheral artery disease [ J ]. Drugs, 2014, 74 ( 9 ):971-980.
  • 10Belardinelli R, Cianci G, Gigli M, et al. Effects oftrimetazidine on myocardial perfusion and left ventricularsystolic function in type 2 diabetic patients with ischemiccardiomyopathy [ J ]. J Cardiovasc Pharmacol,2008,51(6):611-615.

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部